Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ImmunoCellular Therapeutics Announces Issuance of Key Patent for Cancer Vaccine Target

Published: Friday, May 17, 2013
Last Updated: Friday, May 17, 2013
Bookmark and Share
The US Patent and Trademark Office (USPTO) has issued a patent covering methods of use of interleukin 13-receptor alpha 2 protein (IL-13Ra2) in cancer immunotherapy.

IL-13 is an immune regulatory cytokine and IL-13Rα2 is highly and specifically expressed in glioblastoma, ovarian and other solid tumors, but not in normal tissue. IL-13Rα2 is an important target of ImmunoCellular’s lead product candidate, ICT-107, a dendritic cell vaccine directed against glioblastoma antigens and cancer stem cells, as well as ICT-140, a dendritic cell vaccine to treat ovarian cancer.

“We believe that this issued patent will complement and extend the broad intellectual property protection we have established for two of our company’s key assets, ICT-107 and ICT-140, and represents a valuable addition to our patent estate,” said Andrew Gengos, ImmunoCellular Chief Executive Officer. “IL-13Rα2 is a tumor-associated antigen present in the majority of brain cancers, and we believe that using an immunotherapeutic vaccine that targets this and other specific antigens as well as cancer stem cells to stimulate an immune response represents a promising anticancer approach.”

The IL-13Rα2 patent was issued to The Penn State Research Foundation, the technology transfer agent for The Pennsylvania State University, and is licensed to Targepeutics, Inc. ImmunoCellular is a sub-licensee of the patent.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ImmunoCellular Therapeutics Announces Issuance of Key Patent for ICT-121 Cancer Vaccine
Key patent application covers ICT-121, an immunotherapeutic vaccine targeting CD133, an important cancer stem cell marker that is commonly overexpressed on a broad range of solid tumors.
Tuesday, March 05, 2013
ImmunoCellular Therapeutics’ Investigational New Drug Application for ICT-140 Allowed by the FDA
Investigational new drug (IND) application for ICT-140 paves the way for conducting a clinical trial.
Wednesday, January 30, 2013
Scientific News
Untangling Disease-Related Protein Misfolding
Work advances understanding of genetic forms of thrombosis, emphysema, cirrhosis of the liver, neurodegenerative diseases and inflammation, among others.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
"Sunscreen" Gene May Guard Against Melanoma
USC-led study reveals that melanoma patients with deficient or mutant copies of the gene are less protected from harmful ultraviolet rays.
Myeloid-Derived Suppressor Cells Play Role in Tumor Growth
Researchers at Baylor College of Medicine have reported a new mechanism that helps cancer cells engage myeloid-derived suppressor cells.
Drug Might Help Treat Sepsis
A DNA enzyme called Top1 plays a key role in turning on genes that cause inflammation in mouse and human cells in response to pathogens. A drug blocking this enzyme rescued mice from lethal inflammatory responses, suggesting a potential treatment for sepsis.
Large-scale HIV Vaccine Trial to Launch in South Africa
NIH-funded study will test safety, efficacy of vaccine regimen.
Immune System Implicated in Gastroschisis
UCSF researchers show that the immune system is implicated in gastroschisis. The findings could lead to improved treatments for the belly birth defect.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!